SAFETY DATA SHEET

Fidaxomicin Solid Formulation

Version 1.0  Revision Date: 08/15/2019  SDS Number: 4750792-00001  Date of last issue: -

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Fidaxomicin Solid Formulation

Manufacturer or supplier’s details

Company: MSD
Address: 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina C1001AFB
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral): Category 4

GHS label elements
Hazard pictograms:

Signal Word: Warning
Hazard Statements: H302 Harmful if swallowed.
Precautionary Statements:
Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.
SAFETY DATA SHEET

Fidaxomicin Solid Formulation

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>&gt;= 50 -&lt; 70</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 20 -&lt; 30</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>&gt;= 1 -&lt; 5</td>
</tr>
<tr>
<td>Citric acid</td>
<td>77-92-9</td>
<td>&gt;= 1 -&lt; 5</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>TWA</td>
<td>200 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>CMP</td>
<td>10 mg/m³</td>
<td>AR OEL</td>
</tr>
</tbody>
</table>

Further information: Irritation

TWA 10 mg/m³ ACGIH

Engineering measures:
- Use feasible engineering controls to minimize exposure to compound.
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type
  - Hand protection Material: Chemical-resistant gloves

Eye protection:
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
- Work uniform or laboratory coat.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : granules
Color : White to light yellow
Odor : No data available
Odor Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : Not applicable
Relative vapor density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : Not applicable
Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions :
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**
Harmful if swallowed.

**Product:**
- Acute oral toxicity : Acute toxicity estimate: 875,04 mg/kg
- Method: Calculation method

**Components:**

**Fidaxomicin:**
- Acute oral toxicity : LD50 (Rat): > 1.000 mg/kg
  
  LD50 (Dog): > 120 mg/kg

- Acute toxicity (other routes of administration) : LD50 (Rat): 200 mg/kg
  
  Application Route: Intravenous

**Cellulose:**
- Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

- Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
  
  Exposure time: 4 h
  
  Test atmosphere: dust/mist
SAFETY DATA SHEET

Fidaxomicin Solid Formulation

Acute dermal toxicity: LD50 (Rabbit): > 2000 mg/kg

**Sodium benzoate:**
- Acute oral toxicity: LD50 (Rat): > 2000 mg/kg
  Assessment: The substance or mixture has no acute oral toxicity
- Acute dermal toxicity: LD50 (Rabbit): > 2000 mg/kg
  Remarks: Based on data from similar materials

**Citric acid:**
- Acute oral toxicity: LD50 (Mouse): 5400 mg/kg
- Acute dermal toxicity: LD50 (Rat): > 2000 mg/kg
  Method: OECD Test Guideline 402
  Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Sodium benzoate:**
- Species: Rabbit
- Method: OECD Test Guideline 404
- Result: No skin irritation

**Citric acid:**
- Species: Rabbit
- Method: OECD Test Guideline 404
- Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Sodium benzoate:**
- Species: Rabbit
- Result: Irritation to eyes, reversing within 21 days
- Method: OECD Test Guideline 405

**Citric acid:**
- Species: Rabbit
- Result: Irritation to eyes, reversing within 21 days
- Method: OECD Test Guideline 405
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Sodium benzoate:
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Fidaxomicin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
  Test Type: Chromosome aberration test in vitro
  Test system: Chinese hamster ovary cells
  Result: positive
Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Rat
  Application Route: Intravenous
  Result: negative
  Test Type: comet assay
  Species: Rat
  Result: negative

Cellulose:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
  Test Type: In vitro mammalian cell gene mutation test
  Result: negative
Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Result: negative

Sodium benzoate:
SAFETY DATA SHEET

Fidaxomicin Solid Formulation

<table>
<thead>
<tr>
<th>Components</th>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cellulose:</strong></td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td></td>
<td>in vitro micronucleus test</td>
<td>positive</td>
</tr>
<tr>
<td></td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td><strong>Citric acid:</strong></td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td></td>
<td>in vitro micronucleus test</td>
<td>positive</td>
</tr>
<tr>
<td></td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td><strong>Sodium benzoate:</strong></td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td><strong>Reproductive toxicity</strong></td>
<td>Fertility/early embryonic development</td>
<td>negative</td>
</tr>
</tbody>
</table>

Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
- Result: negative
- Test Type: Chromosome aberration test in vitro
- Result: positive

Genotoxicity in vivo
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
- Species: Rat
- Application Route: Ingestion
- Result: negative

Carcinogenicity
- Not classified based on available information.

Components:
- **Cellulose:**
  - Species: Rat
  - Application Route: Ingestion
  - Exposure time: 72 weeks
  - Result: negative
- **Sodium benzoate:**
  - Species: Rat
  - Application Route: Ingestion
  - Exposure time: 24 month(s)
  - Result: negative

Reproductive toxicity
- Not classified based on available information.
Application Route: Intravenous injection  
Fertility: NOAEL: 6,3 mg/kg body weight  

Effects on fetal development: Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 12,6 mg/kg body weight  
Remarks: No significant adverse effects were reported  

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 7 mg/kg body weight  
Remarks: No significant adverse effects were reported  

Cellulose:  
Effects on fertility: Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative  

Effects on fetal development: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative  

Sodium benzoate:  
Effects on fertility: Test Type: Four-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials  

Effects on fetal development: Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  

Citric acid:  
Effects on fetal development: Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative  

STOT-single exposure  
Not classified based on available information.  

STOT-repeated exposure  
Not classified based on available information.
Repeated dose toxicity

**Components:**

**Fidaxomicin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>90 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>28 D</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>62.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 D</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>9,600 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 M</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Vomiting</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>90 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>28 D</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Juvenile rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>200 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>28 D</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt;= 9.000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

**Sodium benzoate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
</tbody>
</table>

**Citric acid:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4,000 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>8,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>10 Days</td>
</tr>
</tbody>
</table>
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Fidaxomicin:

Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, constipation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Fidaxomicin:

Toxicity to algae/aquatic plants:
- EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  Remarks: No toxicity at the limit of solubility.

- NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
- NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l
  Exposure time: 32 d
  Method: OECD Test Guideline 210
  Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 19.6 mg/l
  Exposure time: 21 d
  Method: OECD Test Guideline 211

Toxicity to microorganisms:
- EC50: > 50 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209

- NOEC: 5.9 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish:
- LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  Exposure time: 48 h
  Remarks: Based on data from similar materials

Sodium benzoate:
Toxicity to fish
LC₅₀ (Pimephales promelas (fathead minnow)): 484 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates
EC₅₀ (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants
EC₅₀ (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 32 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Citric acid:
Toxicity to fish
LC₅₀ (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates
EC₅₀ (Daphnia magna (Water flea)): 1.535 mg/l
Exposure time: 24 h

Persistence and degradability
Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Sodium benzoate:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 75 %
Exposure time: 28 d

Citric acid:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential
Components:

Fidaxomicin:
Partition coefficient: n-octanol/water: log Pow: 4.4

Sodium benzoate:
Partition coefficient: n-octanol/water: log Pow: 1.88
Citric acid:
Partition coefficient: n-octanol/water : log Pow: -1.72

Mobility in soil

Components:
Fidaxomicin:
Distribution among environmental compartments : log Koc: 0.80

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Argentina. Carcinogenic Substances and Agents Registry : Not applicable

Control of precursors and essential chemicals for the preparation of drugs : Not applicable

International Regulations
The ingredients of this product are reported in the following inventories:
AICS : not determined
SAFETY DATA SHEET

Fidaxomicin Solid Formulation

SECTION 16. OTHER INFORMATION

Further information

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
AR OEL: Argentina. Occupational Exposure Limits
ACGIH / TWA: 8-hour, time-weighted average
AR OEL / CMP: TLV (Threshold Limit Value)

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and...
shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8